Drug intelligence / Profile preview

BR1018A + BR1018B

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR1018A + BR1018B is a pharmaceutical combination under clinical investigation, co-administered in trials designed to evaluate the pharmacokinetics and safety profiles in healthy volunteers. Developed by Boryung Corp/Boryung Pharmaceutical, the combination aims to address cardiovascular and metabolic indications, specifically essential hypertension and primary hypercholesterolemia. The precise mechanism of action, molecular targets, and composition of BR1018A and BR1018B are not publicly disclosed; available data suggest it is likely a small molecule combination therapy. The combination is being tested as a novel therapeutic regimen for lowering blood pressure and cholesterol levels[1][3][4].

Brand names: BR1018A + BR1018B
Other names: BR1018A + BR1018B

Beyond the preview

Go deeper on BR1018A + BR1018B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1018A + BR1018B.

Explore the full profile